Vidac Pharma Holding Plc | WebDisclosure

Basculer en Français

8295	Companies
114809	Keywords
55260	Articles
62422	Press releases

Headlines Articles Press releases Vidac Pharma Holding Plc

Home
Companies
Vidac Pharma Holding Plc

BRIEF

published on 11/20/2024 at 09:21, 1 day ago

Vidac Pharma Granted Key Patent by USPTO

Clinical Trials Cancer Treatment USPTO Patent Vidac Pharma Hexokinase-2
BRIEF

published on 11/20/2024 at 09:21, 1 day ago

Vidac Pharma obtient un brevet clé de l'USPTO

Essais Cliniques Traitement Du Cancer Brevet USPTO Vidac Pharma Hexokinase-2
PRESS RELEASE

published on 11/20/2024 at 09:16, 1 day ago

Original-Research: Vidac Pharma Holding Plc (von Sphene Capital GmbH): Buy
Update report on Vidac Pharma Holding Plc by Sphene Capital GmbH highlighting the significant patent protection granted by the USPTO for its cancer products, leading to a Buy recommendation with a target price of EUR 4.90

Investment Recommendation USPTO Patent Sphene Capital Vidac Pharma Cancer Products
BRIEF

published on 07/29/2024 at 12:31, 3 months 22 days ago

Sphene Capital Reaffirms 'Buy' Rating for Vidac Pharma Holding

BUY Rating Cancer Therapy Sphene Capital Vidac Pharma VDA-1275
BRIEF

published on 07/29/2024 at 12:31, 3 months 22 days ago

Sphene Capital réaffirme la note « Acheter » de Vidac Pharma Holding

Acheter Une Note Thérapie Contre Le Cancer Sphene Capital Vidac Pharma VDA-1275
PRESS RELEASE

published on 07/29/2024 at 12:26, 3 months 22 days ago

Original-Research: Vidac Pharma Holding Plc (von Sphene Capital GmbH): Buy
Update report by Sphene Capital GmbH highlights promising results of VDA-1275 study by Vidac Pharma Holding Plc in cancer treatment. Buy recommendation maintained with EUR 4.90 target price

Cancer Treatment Sphene Capital GmbH Vidac Pharma Holding VDA-1275 Study EUR 4.90 Target Price
BRIEF

published on 06/12/2024 at 14:41, 5 months 8 days ago

Vidac Pharma Holding Plc: Research Initiation by Sphene Capital GmbH with a Buy Rating

Oncology BUY Rating Biopharmaceutical Clinical-stage Vidac Pharma
BRIEF

published on 06/12/2024 at 14:41, 5 months 8 days ago

Vidac Pharma Holding Plc : Initiation d'une recherche par Sphene Capital GmbH avec une note d'achat

Biopharmaceutique Oncologie Acheter Une Note Vidac Pharma Stade Clinique
PRESS RELEASE

published on 06/12/2024 at 14:36, 5 months 8 days ago

Original-Research: Vidac Pharma Holding Plc (von Sphene Capital GmbH): Buy
Sphene Capital initiates coverage on Vidac Pharma Holding Plc with a Buy rating and a price target of EUR 4.90. Vidac Pharma focuses on reversing cancer cell metabolism for oncology treatments

BUY Rating Sphene Capital GmbH Vidac Pharma Holding Plc Cancer Cell Metabolism Oncology Treatments

Accesswire

Published on 11/21/2024 at 09:00, 50 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 15 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 25 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 50 minutes ago

Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 50 minutes ago

Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 09:41, 9 minutes ago

Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Buy
Published on 11/21/2024 at 09:01, 49 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 08:59, 50 minutes ago

Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 50 minutes ago

Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 35 minutes ago

EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.

Les Echos

Published on 11/21/2024 at 06:58, 2 hours 52 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 52 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 52 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 43 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 30 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE